logo-loader

CB Therapeutics achieved the successful biosynthesis of psilocybin, psilocin

Published: 13:57 05 Jun 2020 BST

CB Therapeutics CEO Sher Butt joined Steve Darling with news the company has recently hit another milestone finding, in early testing, the analysis of raw analytical samples has shown the biosynthetic process of psilocybin, psilocin and related tryptamine-based compounds to be significantly more efficient, of higher purity and less expensive than existing chemical and biosynthetic techniques or other production methods. Butt talks about that and some of the next steps of the company as they prepare to start generating revenue.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

1 hour, 39 minutes ago